Journal
CANCER TREATMENT REVIEWS
Volume 115, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2023.102541
Keywords
Metastatic colorectal cancer; BRAF; Consensus; Treatment
Categories
Ask authors/readers for more resources
This article reviews the current knowledge and consensus management on the clinical management of BRAFV600E-mutant metastatic colorectal cancer (mCRC). The treatment landscape for this specific type of mCRC has changed greatly due to the emergence of molecular targeted therapies and immune checkpoint inhibitors. Tumor tissue analysis for DNA mismatch repair/microsatellite status and KRAS, NRAS, and BRAF mutational status is mandatory for appropriate clinical management and treatment decisions.
Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in approximately 8-12% of patients and is characterised by an aggressive clinical course and poor prognosis. Here we review the current knowledge on BRAFV600E-mutant mCRC and provide a series of consensus statements on its clinical management. The treatment landscape for BRAFV600E-mutant mCRC has changed greatly due to the emergence of molecular targeted therapies (including BRAF inhibitors) and immune checkpoint inhibitors. A scientific literature search identified available data on molecular testing, treatments, and clinical monitoring of patients with BRAFV600E-mutant mCRC. Consensus statements were dis-cussed and developed by a European expert panel. This manuscript provides consensus management guidance for different clinical presentations of BRAFV600E-mutant mCRC and makes recommendations regarding treatment sequencing choices. To guide appropriate clinical management and treatment decisions for mCRC patients, tumour tissue analysis for DNA mismatch repair/microsatellite status and, at a minimum, KRAS, NRAS, and BRAF mutational status is mandatory at the time of diagnosis. Finally, we discuss the rapidly evolving treatment landscape for BRAFV600E-mutant mCRC and define priorities for the development of novel therapeutic strategies that are needed to improve patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available